Core Insights - Cabaletta Bio is advancing its investigational CAR T cell therapy, rese-cel, targeting autoimmune diseases, with a Biologics License Application (BLA) submission planned for 2027 based on a 17-patient cohort study in myositis [1][3] - The company is implementing an automated manufacturing process using Cellares' Cell Shuttle, which could enable production for thousands of patients annually with reduced costs [1][3] - Initial clinical data from trials involving rese-cel with no preconditioning are expected in the first half of 2026, with durability data to follow later in the year [2][7] Clinical Development - Rese-cel is designed to reset the immune system by depleting CD19-positive cells through a single weight-based infusion, aiming for durable clinical responses without chronic therapy [3][5] - The RESET clinical program includes multiple trials across various autoimmune diseases, with pivotal trial designs for systemic lupus erythematosus (SLE) and lupus nephritis (LN) announced, each involving approximately 25 patients [1][3] - The registrational cohort for dermatomyositis and antisynthetase syndrome is currently enrolling, with a primary endpoint focused on improvement while off immunomodulators [3][7] Financial Performance - For the fourth quarter of 2025, research and development expenses were $36.2 million, up from $25.5 million in the same quarter of 2024, while general and administrative expenses were $6.4 million, down from $8.3 million [4][10] - The total net loss for the year ended December 31, 2025, was $167.9 million, compared to a net loss of $115.9 million in 2024 [10] - As of December 31, 2025, the company had cash and equivalents of $133.6 million, a decrease from $164.0 million in 2024, but has since raised an additional $30 million [11][10] Upcoming Milestones - Initial clinical experience with rese-cel manufactured by Cellares is expected in the first half of 2026, which will confirm Good Manufacturing Practice readiness [3][7] - Complete Phase 1/2 data from the RESET-SLE, RESET-SSc, and RESET-MG trials are anticipated to be presented in the first half of 2026, supporting discussions with the FDA on potential registrational pathways [7][3] - The company plans to announce additional clinical data from the RESET trials throughout 2026, including updates on registrational designs for various indications [7][8]

Core Insights - Cabaletta Bio, Inc. announced promising clinical data from its ongoing RESET clinical trials for autoimmune diseases, highlighting the potential of rese-cel to provide drug-free, symptom-free lives for patients [1][2][6] Clinical Trial Results - In the RESET-Myositis trial, 7 out of 8 patients achieved clinically meaningful total improvement scores (TIS) while off all immunomodulators and steroids, with 4 patients experiencing grade 1 cytokine release syndrome (CRS) [1][2][3] - All systemic lupus erythematosus (SLE) patients without nephropathy achieved remission as per DORIS criteria, with 7 out of 7 patients responding clinically while off immunomodulators and glucocorticoids [1][2] - Both patients in the RESET-SSc trial showed significant improvements in modified Rodnan Skin Score (mRSS) after discontinuing immunomodulatory drugs, with one patient meeting the revised Composite Response Index in Systemic Sclerosis (CRISS) criteria [1][8] Safety Profile - Among 18 patients with follow-up of 4 weeks or more, 94% experienced no CRS or only Grade 1 CRS, and 89% had no immune effector cell-associated neurotoxicity syndrome (ICANS) [1][2] - In the RESET-SLE trial, 2 out of 8 patients experienced grade 1 CRS, and one ICANS event was reported [3][8] Regulatory and Development Plans - Cabaletta plans to initiate enrollment in two registrational myositis cohorts in 2025 and has scheduled discussions with the FDA regarding registrational pathways for SLE/LN in 3Q25, scleroderma in 4Q25, and myasthenia gravis in 1H26 [1][9] - The RESET clinical trial program is accelerating, with 51 patients actively enrolled across over 65 clinical sites as of May 30, 2025 [1][2][6] Company Overview - Cabaletta Bio is focused on developing curative targeted cell therapies for autoimmune diseases, with rese-cel being a key investigational therapy designed to deplete CD19-positive B cells [5][6] - The company aims to change treatment paradigms for autoimmune diseases through its innovative CARTA platform, which includes multiple disease-specific clinical trials [5][6]

Core Insights - Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing curative targeted cell therapies for autoimmune diseases [3] - The company will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025 [1] - The lead strategy, CARTA, is centered on the investigational therapy rese-cel, which is currently in the RESET clinical development program [3] Company Overview - Cabaletta Bio is dedicated to advancing engineered T cell therapies that may provide deep and durable, potentially curative treatments for a variety of autoimmune diseases [3] - The company is headquartered in Philadelphia, PA, and has a comprehensive platform that includes two complementary strategies for therapy development [3] - Rese-cel is a fully human CD19-CAR T cell therapy that contains 4-1BB and is being evaluated across multiple therapeutic areas, including rheumatology, neurology, and dermatology [3]